Denali Therapeutics Stock Probability of Future Stock Price Finishing Over 24.22
| DNLI Stock | USD 24.69 0.47 1.94% |
Denali |
Denali Therapeutics Target Price Odds to finish over 24.22
The tendency of Denali Stock price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
| Current Price | Horizon | Target Price | Odds to stay above $ 24.22 in 90 days |
| 24.69 | 90 days | 24.22 | about 92.63 |
Based on a normal probability distribution, the odds of Denali Therapeutics to stay above $ 24.22 in 90 days from now is about 92.63 (This Denali Therapeutics probability density function shows the probability of Denali Stock to fall within a particular range of prices over 90 days) . Probability of Denali Therapeutics price to stay between $ 24.22 and its current price of $24.69 at the end of the 90-day period is under 4.
Given the investment horizon of 90 days the stock has the beta coefficient of 2.46 suggesting as the benchmark fluctuates upward, the company is expected to outperform it on average. However, if the benchmark returns are projected to be negative, Denali Therapeutics will likely underperform. Additionally Denali Therapeutics has a negative alpha, implying that the risk taken by holding this instrument is not justified. The company is significantly underperforming the Dow Jones Industrial. Denali Therapeutics Price Density |
| Price |
Predictive Modules for Denali Therapeutics
There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as Denali Therapeutics. Regardless of method or technology, however, to accurately forecast the stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.Denali Therapeutics Risk Indicators
For the most part, the last 10-20 years have been a very volatile time for the stock market. Denali Therapeutics is not an exception. The market had few large corrections towards the Denali Therapeutics' value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold Denali Therapeutics, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of Denali Therapeutics within the framework of very fundamental risk indicators.α | Alpha over Dow Jones | -0.2 | |
β | Beta against Dow Jones | 2.46 | |
σ | Overall volatility | 2.16 | |
Ir | Information ratio | -0.0065 |
Denali Therapeutics Alerts and Suggestions
In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of Denali Therapeutics for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for Denali Therapeutics can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.| Denali Therapeutics had very high historical volatility over the last 90 days | |
| The company reported the previous year's revenue of 330.53 M. Net Loss for the year was (145.22 M) with loss before overhead, payroll, taxes, and interest of (250.27 M). | |
| Denali Therapeutics currently holds about 1.07 B in cash with (357.99 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 8.66. | |
| Denali Therapeutics has a poor financial position based on the latest SEC disclosures | |
| Over 91.0% of the company shares are held by institutions such as insurance companies | |
| Latest headline from news.google.com: Denali Therapeutics Inc. Receives 38.90 Consensus Target Price from Brokerages - MarketBeat |
Denali Therapeutics Price Density Drivers
Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of Denali Stock often depends not only on the future outlook of the current and potential Denali Therapeutics' investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Denali Therapeutics' indicators that are reflective of the short sentiment are summarized in the table below.
| Common Stock Shares Outstanding | 137.4 M | |
| Cash And Short Term Investments | 1 B |
Denali Therapeutics Technical Analysis
Denali Therapeutics' future price can be derived by breaking down and analyzing its technical indicators over time. Denali Stock technical analysis helps investors analyze different prices and returns patterns as well as diagnose historical swings to determine the real value of Denali Therapeutics. In general, you should focus on analyzing Denali Stock price patterns and their correlations with different microeconomic environments and drivers.
Denali Therapeutics Predictive Forecast Models
Denali Therapeutics' time-series forecasting models is one of many Denali Therapeutics' stock analysis techniques aimed to predict future share value based on previously observed values. Time-series forecasting models are widely used for non-stationary data. Non-stationary data are called the data whose statistical properties, e.g., the mean and standard deviation, are not constant over time, but instead, these metrics vary over time. This non-stationary Denali Therapeutics' historical data is usually called time series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the stock market movement and maximize returns from investment trading.
Things to note about Denali Therapeutics
Checking the ongoing alerts about Denali Therapeutics for important developments is a great way to find new opportunities for your next move. Our stock alerts and notifications screener for Denali Therapeutics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.
| Denali Therapeutics had very high historical volatility over the last 90 days | |
| The company reported the previous year's revenue of 330.53 M. Net Loss for the year was (145.22 M) with loss before overhead, payroll, taxes, and interest of (250.27 M). | |
| Denali Therapeutics currently holds about 1.07 B in cash with (357.99 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 8.66. | |
| Denali Therapeutics has a poor financial position based on the latest SEC disclosures | |
| Over 91.0% of the company shares are held by institutions such as insurance companies | |
| Latest headline from news.google.com: Denali Therapeutics Inc. Receives 38.90 Consensus Target Price from Brokerages - MarketBeat |
Check out Denali Therapeutics Backtesting, Denali Therapeutics Valuation, Denali Therapeutics Correlation, Denali Therapeutics Hype Analysis, Denali Therapeutics Volatility, Denali Therapeutics History as well as Denali Therapeutics Performance. For more detail on how to invest in Denali Stock please use our How to Invest in Denali Therapeutics guide.You can also try the Portfolio Holdings module to check your current holdings and cash postion to detemine if your portfolio needs rebalancing.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Denali Therapeutics. If investors know Denali will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Denali Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.76) | Quarterly Revenue Growth (1.00) | Return On Assets (0.24) | Return On Equity (0.35) |
The market value of Denali Therapeutics is measured differently than its book value, which is the value of Denali that is recorded on the company's balance sheet. Investors also form their own opinion of Denali Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Denali Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Denali Therapeutics' market value can be influenced by many factors that don't directly affect Denali Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Denali Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Denali Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Denali Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.